Oct 20 (Reuters) - Doxa Ab ::Q3 net sales sek 3.4 million versus sek 4.0 million year ago.Q3 net loss sek 2.3 million versus loss sek 2.9 million year ago.
Oct 20 (Reuters) - PLEDPHARMA AB (PUBL) ::Q3 NET LOSS SEK 27.3 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO.
Oct 20 (Reuters) - THROMBOGENICS NV ::CASH AND INVESTMENTS €113.4 MILLION AS OF END OF SEPT. 2017 VERSUS €65.1 MILLION AT END OF JUNE 2017.ANNOUNCES NOVARTIS WILL INVEST €10 MILLION IN THROMBOGENICS CAPITAL.
Oct 20 (Reuters) - BB BIOTECH AG ::PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER.Q3 NET PROFIT AMOUNTED TO CHF 365 MN VERSUS PROFIT OF CHF 392 MN REPORTED IN Q3 LAST YEAR.
Oct 19 (Reuters) - Ignyta Inc ::Ignyta announces pricing of public offering of common stock.Says public offering of 10.0 million common shares priced at $16.00per share.
Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint.Durect Corp - results from phase 3 clinical trial for Posimir trended in favor of Posimir versus comparator, but did not achieve statistical significance.
Oct 20 (Reuters) - Biopharmx Corp :Biopharmx Corp files for offering of up to $40.3 million of shares of common stock - SEC filing.
Oct 20 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - on Oct. 18, David-Alexander C. Gros resigned as president, COO and interim CFO of co, effective as of Oct. 19 - SEC filing.Neurocrine Biosciences Inc - in connection with resignation of Gros, effective Oct. 19, Kevin C. Gorman was appointed as company's interim CFO.
Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock by the selling stockholders - SEC filing.